Skip to content

Disease-syndrome Characteristics of IPF

Research on the Disease-syndrome Characteristics of Idiopathic Pulmonary Fibrosis

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07178392
Enrollment
2864
Registered
2025-09-17
Start date
2025-09-15
Completion date
2028-11-30
Last updated
2025-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Keywords

Idiopathic Pulmonary Fibrosis, TCM, Epidemiological investigation, characteristics

Brief summary

This study, based on previous registration records, aims to explore the syndrome patterns, disease characteristics, and their interrelationships of IPF at different stages, grades, and in its natural course, thus providing a multidimensional interpretation of the syndrome patterns and characteristics of IPF.

Detailed description

This study, based on previous registration records, uses a cross-sectional survey design to collect demographic information, disease-related data, syndrome data, and auxiliary examination data from 2864 IPF patients in China. It aims to elucidate the syndrome types, disease characteristics, and the interrelationships between them of IPF at different stages, grades, and in its natural course.

Interventions

None listed

Sponsors

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
CollaboratorOTHER
China-Japan Friendship Hospital
CollaboratorOTHER
The First Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
Shanghai Pulmonary Hospital, Shanghai, China
CollaboratorOTHER
Henan University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients diagnosed with IPF; 2. Age ≥ 18 years old; 3. Voluntarily participate in this study and sign an informed consent form.

Exclusion criteria

1. Patients with confusion, dementia, consciousness disorders, and various mental illnesses; 2. Those who are unable to take care of themselves and have been bedridden for a long time.

Design outcomes

Primary

MeasureTime frameDescription
Disease StageEvaluate at baseline.Recording the disease staging of IPF patients. According to the Adult Idiopathic Pulmonary Fibrosis (Revised Edition) and Progressive Pulmonary Fibrosis: ATS/ERS/JRS/ALAT Official Clinical Practice Guidelines (2022 Edition), and the Chinese Expert Consensus on the Diagnosis and Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis, the disease staging evaluation of IPF is stable phase or acute exacerbation.
Gender, age and physiologic variables (GAP)stageEvaluate at baseline.Recording the GAP stage of IPF patients. GAP stage is a risk stratification method that quantifies the three core parameters of patients: gender, age, and physiological parameters, by calculating the total score and conducting risk stratification.
Pulmonary function classificationEvaluate at baseline.Recording the pulmonary function classification of IPF patients. According to The Expert Consensus on the Diagnostic Criteria for Adult Lung Function in China, pulmonary function classification is divided into mild, moderate, and severe grades.
Natural courseEvaluate at baseline.Recording the natural course of IPF patient. According to international research, the natural course of IPF can be divided into stable, slow progression, rapid progression, and recurrent acute exacerbation. The specific criteria are as follows: 1.stable: FVC annual decline\<0.13L; 2. stable slow progression: FVC annual decline 0.13L-0.21L; 3. Rapid progress: FVC annual decline\>0.21L; 4. Recurrent acute exacerbations: Annual number of acute exacerbations ≥ 1.
The Traditional Chinese Medicine(TCM) SyndromesEvaluate at baseline.Evaluate traditional Chinese medicine syndromes by collecting patients' symptoms, signs, and tongue pulse information.
6 Six Minute Walk Distance(6MWD)Evaluate at baseline.6MWD will be applied to evaluate the exercise capacity. The higher values indicate the better exercise capacity.
The 30 - second sit - to - stand test(30s STS)Evaluate at baseline.The 30 second sitting and standing test will be used to evaluate lower limb strength and cardiopulmonary function.
A Tool to Assess Quality of life (ATAQ-IPF) total scoresEvaluate at baseline.ATAQ-IPF is currently a specialized scale for evaluating the quality of life, consisting of 13 dimensions and 74 items, with each item scored on a 1-5 scale. The higher the score, the worse the quality of life.
St. George's respiratory questionnaire (SGRQ) total scoresEvaluate at baseline.SGRQ is a scale used to evaluate the quality of life of patients, which includes three dimensions: symptoms, mobility, and the impact of disease on daily life, with a total of 50 items. The total score range of SGRQ is usually between 0 and 100, with higher scores leading to poorer quality of life.
DyspneaEvaluate at baseline.Dyspnea will be assessed by modified Medical Research Council(mMRC) scores. A score of 0-4 will be givenaccording to the degree of immediate dyspnea. A higher score indicates a worse condition.
C-reactive protein (CRP)Evaluate at baseline.The CRP level will be detected by ELISA technology.
Krebs Von den Lungen-6(KL-6)Evaluate at baseline.The KL-6 level will be detected by ELISA technology.
The pulmonary artery systolic pressure(PASP)Evaluate at baseline.The PASP will be measured byechocardiogram.
The diameter of the pulmonary arteryEvaluate at baseline.The diameter of the pulmonary artery will be measured byechocardiogram.
Forced vital capacity (FVC)Evaluate at baseline.FVC will be applied to assess pulmonary function.
FVC as the percentage of the predicted value (FVC%)Evaluate at baseline.FVC% will be applied to assess pulmonary function.
Diffusing capacity of the lungs for carbon monoxide (DLCO)Evaluate at baseline.DLCO will be applied to assess pulmonary function.
DLCO as the percentage of the predicted value (DLCO%)Evaluate at baseline.DLCO% will be applied to assess pulmonary function.

Countries

China

Contacts

Primary Contactxueqing yu, Ph.D
yxqshi@163.com+8613525518843
Backup Contactjiansheng li, Professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026